JOP20180027A1 - بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها - Google Patents

بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها

Info

Publication number
JOP20180027A1
JOP20180027A1 JOP/2018/0027A JOP20180027A JOP20180027A1 JO P20180027 A1 JOP20180027 A1 JO P20180027A1 JO P20180027 A JOP20180027 A JO P20180027A JO P20180027 A1 JOP20180027 A1 JO P20180027A1
Authority
JO
Jordan
Prior art keywords
polypeptide
ligand
binding domain
plasma membrane
methods
Prior art date
Application number
JOP/2018/0027A
Other languages
English (en)
Inventor
Peter Emtage
Levi Rupp
Stephen Santoro
Scott Coyle
Original Assignee
Cell Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Design Labs Inc filed Critical Cell Design Labs Inc
Publication of JOP20180027A1 publication Critical patent/JOP20180027A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7153—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for colony-stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Abstract

يتم تقديم طرق و تراكيب لتحديد موقع البروتينات بشكل عكسي إلى الجزء الخارجي من سطح الخلية. يمكن أن تشتمل التراكيب الواردة هنا على الأحماض النووية التي تُشفر البولبيبتيدات المعنية و مجال ربط جزىء الارتباط (LBD) لمستقبل الهرمون النووي. عند إضافة جزىء الارتباط، يمكن للبوليبيبتيد أن يتموضع للجانب الخليوي الخارجي لغشاء البلازما. إزالة جزىء الارتباط يمكن أن يؤدي الى إزالة البوليبيبتيد من سطح الخلية. في بعض التجسيدات، يمكن لتركيبة حمض نووي تتضمن LBD أن تندمج في بوليبيبتيد يتضمن مجال ربط لمولد مضاد (على سبيل المثال، مستقبل مولد مضاد مخلط). في بعض التجسيدات، يمكن إدخال مثل هذا البوليبيبتيد في خلية الثدييات، عند دخول جزىء الارتباط للخلية، يتموضع مجال ربط مولد المضاد في البوليبيبتيد للجانب الخليوي الخارجي لغشاء البلازما و عند إزالة جزىء الارتباط يُزال مجال ربط مولد المضاد في البوليبيبتيد من الجانب الخليوي الخارجي لغشاء البلازما . تم تقديم تطبيقات طبية تشمل السيطرة على سمية خلايا CAR T.
JOP/2018/0027A 2017-03-28 2017-03-28 بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها JOP20180027A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762477733P 2017-03-28 2017-03-28
US201762587262P 2017-11-16 2017-11-16

Publications (1)

Publication Number Publication Date
JOP20180027A1 true JOP20180027A1 (ar) 2019-01-30

Family

ID=62090037

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2018/0027A JOP20180027A1 (ar) 2017-03-28 2017-03-28 بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها

Country Status (14)

Country Link
US (2) US11111310B2 (ar)
EP (1) EP3601330A1 (ar)
JP (2) JP2020512009A (ar)
KR (3) KR20240019863A (ar)
CN (1) CN110678480A (ar)
AU (3) AU2018244592C1 (ar)
BR (1) BR102018006205A2 (ar)
CA (1) CA3058262A1 (ar)
IL (1) IL269433A (ar)
JO (1) JOP20180027A1 (ar)
SG (2) SG11201908618SA (ar)
TW (1) TWI811212B (ar)
UY (1) UY37644A (ar)
WO (1) WO2018183551A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20190431A (es) * 2017-03-27 2019-11-01 Hoffmann La Roche Formatos mejorados de receptor de unión a antígeno
US11485789B2 (en) * 2017-11-12 2022-11-01 Jay H. Choi Modular, controlled single chain variable fragment antibody switch
WO2021076958A1 (en) * 2019-10-18 2021-04-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of tim-3 cytoplasmic tail in chimeric antigen receptors
CN111995689B (zh) * 2020-08-27 2023-05-05 深圳市体内生物医药科技有限公司 一种基因修饰的免疫细胞及其制备方法和应用
CN114149510B (zh) * 2021-10-29 2024-01-30 上海鑫湾生物科技有限公司 一种条件控制的可剪接嵌合抗原受体分子及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
JP3700791B2 (ja) * 1994-05-26 2005-09-28 小野薬品工業株式会社 Ｆａｓ抗原融合蛋白、その蛋白をコードするＤＮＡ、そのＤＮＡを含むベクター、そのベクターで形質転換された宿主細胞、そのベクターを有効成分とする治療剤、およびその宿主細胞を用いるスクリーニング方法
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US5925549A (en) * 1996-04-15 1999-07-20 The Board Of Trustees Of The Leland Stanford Junior University Soluble 7-transmembrane domain G-protein-coupled receptor compositions and methods
JP2002153287A (ja) * 2000-11-24 2002-05-28 Daicel Chem Ind Ltd 内分泌撹乱物質結合領域を細胞の表層に有する微生物およびその応用方法
WO2002095405A1 (en) 2001-05-21 2002-11-28 The Regents Of The University Of California Membrane-resident steroid receptors and methods of use thereof
EP1912069A3 (en) * 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US20060040354A1 (en) 2004-07-20 2006-02-23 O'keefe Theresa L Novel polyadenylation signal for use in expression vectors
TW200724679A (en) * 2005-05-19 2007-07-01 Schering Ag Treatment of disease using an improved regulated expression system
CN101292160A (zh) * 2005-05-26 2008-10-22 达娜-法勃肿瘤研究所公司 Muc1-依赖性的抗-雌激素抗性的调节
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
JP2013503607A (ja) 2009-09-01 2013-02-04 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
RU2012119756A (ru) 2009-10-15 2013-11-20 Эбботт Лэборетриз Иммуноглобулины с двумя вариабельными доменами и их применение
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
KR20210147101A (ko) 2013-02-15 2021-12-06 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 키메라 항원 수용체 및 이의 이용 방법
WO2014151960A2 (en) * 2013-03-14 2014-09-25 Bellicum Pharmaceuticals, Inc. Methods for controlling t cell proliferation
CA2956667A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US10934346B2 (en) * 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
US20170081411A1 (en) * 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
GB201405845D0 (en) * 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
CN106535925A (zh) * 2014-05-23 2017-03-22 佛罗里达大学研究基金会有限公司 基于car的免疫治疗
US10538568B2 (en) * 2014-11-04 2020-01-21 The Trustees Of The University Of Pennsylvania Methods and compositions of a follicle stimulating hormone receptor immunoreceptor
CN108064283B (zh) * 2015-02-24 2024-01-09 加利福尼亚大学董事会 结合触发的转录开关及其使用方法
SG11201707652WA (en) * 2015-03-30 2017-10-30 Intrexon Corp Ligand inducible polypeptide coupler system
US10988542B2 (en) * 2015-08-24 2021-04-27 Cellectis Chimeric antigen receptors with integrated controllable functions
SG11201804038VA (en) * 2016-01-08 2018-06-28 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof

Also Published As

Publication number Publication date
KR20230004870A (ko) 2023-01-06
KR102475696B1 (ko) 2022-12-09
US20180319890A1 (en) 2018-11-08
AU2018244592A1 (en) 2019-10-03
AU2021203626A1 (en) 2021-07-01
KR20220002751A (ko) 2022-01-06
KR20240019863A (ko) 2024-02-14
SG11201908618SA (en) 2019-10-30
AU2018244592C1 (en) 2021-07-08
TWI811212B (zh) 2023-08-11
CN110678480A (zh) 2020-01-10
AU2021203626B2 (en) 2023-03-09
IL269433A (en) 2019-11-28
TW201840590A (zh) 2018-11-16
SG10201912408WA (en) 2020-02-27
US20210395386A1 (en) 2021-12-23
AU2023200894A1 (en) 2023-03-23
JP2020512009A (ja) 2020-04-23
JP2022058725A (ja) 2022-04-12
AU2018244592B2 (en) 2021-03-11
BR102018006205A2 (pt) 2021-03-23
US11111310B2 (en) 2021-09-07
JP7433348B2 (ja) 2024-02-19
KR20190133734A (ko) 2019-12-03
CA3058262A1 (en) 2018-10-04
UY37644A (es) 2018-10-31
WO2018183551A1 (en) 2018-10-04
EP3601330A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
JOP20180027A1 (ar) بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها
MX2019000863A (es) Usos de vesicula extracelular que comprende una proteina de fusion que tiene capacidad de union a fc.
PH12018502191A1 (en) Compositions and methods for selective protein expression
PH12019501413A1 (en) T-cell modulatory multimeric polypeptides and method of use thereof
PH12018502213A1 (en) Anti-myostatin antibodies and methods of use
SG10201913583QA (en) Proteolytically cleavable chimeric polypeptides and methods of use thereof
WO2014116846A3 (en) Methods and compositions for modulating an immune response
AU2017266905A1 (en) Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
MX2019002903A (es) Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos.
CL2018000324A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
BR112016023507A2 (pt) marcadores genéticos transgene e métodos de uso
GB2549632A (en) Fusion protein comprising three binding domains to 5TA and CD3
WO2014164348A3 (en) Modified caspase polypeptides and uses thereof
EA201691669A1 (ru) Связывающие сывороточный альбумин домены фибронектина iii типа
MY181199A (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
PH12020550240A1 (en) D-domain containing polypeptides and uses thereof
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
PH12014501912A1 (en) Cx3cr1-binding polypeptides
WO2011082087A8 (en) Dps fusion proteins for use in vaccines and diagnostics
WO2012009704A3 (en) Novel peptides and uses thereof
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
WO2015120542A8 (en) Hybrid proteins and uses thereof
MX2021004470A (es) Vesículas extracelulares para terapias dirigidas contra células supresoras de origen mieloide.